BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Quarterly Reports

Q3 2019 Report

Tuesday, 19 NovemberArctic Securities, Haakon VIIs gate 5, Oslo

The webcast will be streamed LIVE and the recording will be available after LIVE session is finished.

Link to live webcast

Corporate Presentation

Solebury Trout Virtual Global Healthcare Conference

31 March 2020

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019

BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS

More News

Scientific Presentations

ASH 2019, Sonja Loges et al

9 December 2019Orlando, USA

Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.

Read More

Annual Report 2019

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BERGENBIO TO PRESENT AT THE UPCOMING 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE

Fourth quarter and full year 2019 results presentation and webcast

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

Third quarter 2019 results presentation and webcast

Meet us in Maryland during SITC 2019!

More Events